Communiqués Immutep ADR Deutsche Boerse AG

Actions

YP1A

US45257L1089

Marché Fermé - Deutsche Boerse AG Autres places de cotation 09:50:54 28/06/2024			Varia. 5j.	Varia. 1 janv.
1,85 ^EUR	+1,65 %		-20,26 %	-12,74 %

27/06	Wall Street devrait ouvrir en légère baisse jeudi, les investisseurs analysant les données économiques positives	MT
27/06	Immutep annonce des résultats positifs dans un essai de combinaison de médicaments pour le traitement du cancer de la tête et du cou	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Immutep Reports Positive Topline Results from TACTI-003 Phase IIb Trial in First Line Head and Neck Cancer	28/06	AQ
Immutep Limited (IMM) \| TACTI-003: the real results; Maintain Overweight A$1.13 PT (Analysts: Dr Melissa Benson and Dr Shane Storey)	27/06	PU
Immutep : Global Webcast Slides for New Efti Clinical Data in 1st Line HNSCC	27/06	PU
Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer	25/06	AQ
Immutep : successfully completes institutional placement and institutional component of entitlement offer	05/06	PU
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial	03/06	AQ
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024	15/05	AQ
Immutep : ESMO Breast 2024 AIPAC 003 Poster (Metastatic Breast Cancer)	15/05	PU
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	02/05	AQ
Immutep Quarterly Activities Report Q3 FY24	29/04	AQ
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761	18/04	AQ
Wilsons - Adding Autoimmune to the indication list; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)	18/04	PU
Immutep : Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP76	18/04	PU
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	17/04	AQ
Immutep : Corporate Presentation	26/03	PU
Ladenburg Thalmann - Next Is Dose Optimization for BC Program; Reiterate Buy, $8.30 PT (Analyst: Ahu Demir, PhD)	06/03	PU
Wilsons - Dose it higher? Now an option; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)	05/03	PU
Immutep Announces First Clinical Data from 90mg Dosing of Efti	05/03	AQ
Immutep Quarterly Activities Report Q2 FY24	30/01	AQ
First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer	04/01	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Immutep ADR Deutsche Boerse AG

Actions

YP1A

US45257L1089

Communiqués

Filtres